HCPLive

Gastroesophageal Reflux Disease (GERD) 
The MD Magazine Gastroesophageal Reflux Disease (GERD) condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

Latest Headlines

Five Categories of Lower Gastrointestinal Functional Bowel Disorders in Revised Rome IV Criteria
The new Rome IV criteria classify the functional bowel disorders into five distinct categories, including irritable bowel syndrome (IBS), functional constipation, functional diarrhea, functional abdominal bloating/distention, and unspecified functional bowel disorder. A new category for opioid-induced constipation, which is distinct from the functional bowel disorders, has been added.
Rome IV updates include more specific definitions and diagnostic criteria for functional gastroduodenal disorders such as functional dyspepsia, belching disorders, and nausea and vomiting disorders.
The Rome Foundation announced the release of updated and revised Rome IV diagnostic criteria for more than 20 different gastrointestinal disorders at DDW 2016.
Gastroesophageal reflux disease (GERD) has long been thought to result from built up stomach acid damaging the lining of the esophagus.
The field of gastroenterology is as wide as the the amount of the body that it covers. Because of this there are certain challenges doctors face whether they treat the entire gastrointestinal system or just specific parts.
The US Food and Drug Administration (FDA) has approved dexlansoprazole (Dexilant SoluTab/Takeda Pharmaceuticals), a new formulation for the treatment of heartburn-associated gastroesophageal reflux disease (GERD) in adults age 18 and older.
Raised lesions of dysplatic Barrett's esophagus (BE) are treated with endoscopic mucosal resection (EMR) before ablation. But the procedure causes bleeding in 10% of cases.Mayo Clinic researchers said they found a way to reduce those adverse events.
The LINX Reflux Management System was recently shown to successfully control reflux-related symptoms in patients with gastroesophageal reflux disease (GERD), reducing their need to continue treatment with proton pump inhibitors (PPIs) and other acid-suppression medications.

Most Popular

@MDMagazine

$vacMongoViewPlus$ $vAR$